Advertisement
News
Advertisement

EnteroMedics to Present at the 9th Annual Craig-Hallum Institutional Investor Conference

Tue, 05/29/2012 - 6:45am
The Associated Press

EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices

using neuroblocking technology to treat obesity, metabolic diseases

and other gastrointestinal disorders, today announced that Mark B.

Knudson, PhD President and Chief Executive Officer, is scheduled to

present at the 9th Annual Craig-Hallum Institutional Investor

Conference on Wednesday, May 30, 2012 at 10:55 am Central Time, at the

Minneapolis Marriott City Center Minneapolis, Minnesota. Dr. Knudson

will provide an overview of the Company and an update on its VBLOC@

vagal blocking therapy development program.

The conference will not be webcast. Institutional investors who wish

to request a meeting with EnteroMedics should contact Craig-Hallum.

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development

and commercialization of its neuroscience based technology to treat

obesity and metabolic diseases. EnteroMedics' proprietary technology,

VBLOC@ vagal blocking therapy, delivered by a pacemaker-like device

called the Maestro@ Rechargeable System, is designed to intermittently

block the vagus nerves using high-frequency, low-energy, electrical

impulses. VBLOC allows people with obesity to take a positive path

towards weight loss, addressing the lifelong challenge of obesity and

its comorbidities without sacrificing wellbeing or comfort.

EnteroMedics has received CE Mark and is listed on the Australian

Register of Therapeutic Goods.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about

EnteroMedics Inc. Our actual results could differ materially from

those discussed due to known and unknown risks, uncertainties and

other factors including our limited history of operations; our losses

since inception and for the foreseeable future; our lack of commercial

regulatory approval for our Maestro@ System for the treatment of

obesity in the United States or in any foreign market other than

Australia and the European Community; our preliminary findings from

our EMPOWER? pivotal trial; our ability to comply with the Nasdaq

continued listing requirements; our ability to commercialize our

Maestro System; our dependence on third parties to initiate and

perform our clinical trials; the need to obtain regulatory approval

for any modifications to our Maestro System; physician adoption of our

Maestro System and VBLOC@ vagal blocking therapy; our ability to

obtain third party coding, coverage or payment levels; ongoing

regulatory compliance; our dependence on third party manufacturers and

suppliers; the successful development of our sales and marketing

capabilities; our ability to raise additional capital when needed;

international commercialization and operation; our ability to attract

and retain management and other personnel and to manage our growth

effectively; potential product liability claims; potential healthcare

fraud and abuse claims; healthcare legislative reform; and our ability

to obtain and maintain intellectual property protection for our

technology and products. These and additional risks and uncertainties

are described more fully in the Company's filings with the Securities

and Exchange Commission, particularly those factors identified as

"risk factors" in the annual report on Form 10-K filed March 15, 2012.

We are providing this information as of the date of this press release

and do not undertake any obligation to update any forward-looking

statements contained in this document as a result of new information,

future events or otherwise.

Caution - Investigational device. Limited by Federal (United States)

law to investigational use. . EnteroMedics has received CE Mark and is

listed on the Australian Register of Therapeutic Goods.

The implantation procedure and usage of the Maestro@ System carry some

risks, such as the risks generally associated with laparoscopic

procedures and those related to treatment as described in the ReCharge

clinical trial informed consent.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading